Fintel reports that on January 10, 2025, Roth MKM initiated coverage of Verona Pharma plc - Depositary Receipt () ...
Physicians recommend that patients with chronic obstructive pulmonary disease (COPD) quit smoking and use steroids, ...
For patients with COPD, budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol.
Boobalan Pachaiyappan, an analyst from Roth MKM, has initiated a new Buy rating on Verona Pharma (VRNA).Stay Ahead of the Market:Discover ...
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
While wildfires can cause immediate destruction to homes and towns, a few weeks of smoke exposure should not have long-term ...
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is ...
A study reveals childhood smoking significantly increases COPD risk in adulthood, highlighting the need for targeted ...
The Texas Tech University Health Sciences Center is offering a new treatment for patients suffering from severe chronic ...
Additional research addressing the connection between chronic obstructive pulmonary disease (COPD) and metabolic syndrome is needed to improve holistic patient care, according to a new editorial.
Verona Pharma’s Ohtuvayre has a solid market entry, but its valuation is high. Read why VRNA stock remains a buy for ...